Telangana businessman claims credit for cap on retail price of cancer drugs

Tractor dealer Purushottam Somani contacted PMO after finding difference of up to 1,000 per cent between wholesale price and MRP, says diabetes and other drugs next on radar

The company already enjoys a 67-68 per cent share of the respiratory drugs market in India and has potential for a 14-15 per cent growth
The company already enjoys a 67-68 per cent share of the respiratory drugs market in India and has potential for a 14-15 per cent growth
BS Reporter Hyderabad
Last Updated : Mar 05 2019 | 6:22 PM IST
A businessman from a Telangana town, who claims he played a major role in influencing the recent cap on the MRP of cancer drugs imposed by the Government of India, says similar price controls on drugs for treating ailments like diabetes were in the offing to save people from 'retail loot'.

Founder of Nizamabad Chamber of Commerce and Industry and a local tractor dealer, Purushottam Somani had found a huge difference of as much as 1,000 per cent in some cases, between the price at first point of sale (wholesale price) and the MRP levied on medicines of non-scheduled category formulations.

Somani started corresponding with the Prime Minister's office in October 2018 on this issue. Later, he met with Union Health Minister J P Nadda and Union Minister for Chemicals and Fertilisers D V Sadananda Gowda and other senior officials seeking action on this 'pricing scandal'. 

BJP national vice president and Rajya Sabha member, Vinay Sahasrabuddhe, who had taken up this matter with Prime Minister Narendra Modi, has endorsed Somani's efforts: "Dear Purushottam Ji, Many thanks. Firstly, it is entirely to your credit that some justice has been done to the important subject that you are very passionately fighting for. I admire your emphatic follow-up for a very worthy cause..," Sahasrabuddhe said in an e-mail to Somani on Monday.

Somani's involvement and activism essentially embraced the issue of high retail margins on medicines that fall outside the Drug Price Control (DPC) regime. The businessman says he started studying medicine prices end-to-end after a poor man took a Rs 40,000 loan to get treatment for a small ailment. 

He claimed drug companies had adopted the practice of fixing the MRP of a product several times of the price at which they sell to a stockist, only to incentivise doctors, hospitals and retail stores to give preference to their products over other generics.

The retail price of cancer drug Pegfilgrastim, manufactured by a Hyderabad-based company, was reduced to Rs 2,720 inclusive of GST, from Rs 10,790 after the government announced a new price formula that permitted a 30 per cent trade margin, according to Somani.

"I am telling you that this government is going to bring similar price controls on medicines used for other major ailments such as diabetes, besides surgicals, after the elections are over," Somani said at a press conference in Hyderabad on Tuesday.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story